How would you characterize the clinical results thus far in a Phase I study of the company's vaccine for heavily pretreated metastatic synovial sarcoma and myxoid/round cell sarcoma? Company claims their cancer vaccine in metastatic STS (synovial sarcoma and myxoid/round cell liposarcoma) (n=24), 80% 1 year survival, with 58% DCR (1 PR/13 SD), PFS 4.6 months.   

Company claims as of June 2016 “mOS not reached - median follow up 640 days (21.3 months)”.  If the trial is still ongoing, does this mean that mOS is certain to be greater than 640 days (21.3 months)?

What is your experience of the current toxicity of first line olaratumab and doxorubincin?

Assuming median survival with for this experimental treatment remained approximately 21.3 months, but with no grade 3+ or above toxicity, how would this impact olaratumab/doxorubicin as a first line treatment?

Is it meaningful that the PFS of first line olara+dox (8 months) appears to be significantly more than current PFS of the trial (4 months)? Or is it meaningless given the survival numbers are about the same? Is this evidence that vaccines deliver survival without responses as measure by tumor size decreases?  Does it make a difference that this trial used a modified definition of response (irRC as opposed to RECIST)?

Of the following types of treatments for sarcoma, which do you think are the most promising: targeted therapies (e.g kinase inhibitors), combination chemotherapies, checkpoint inhibitors, cancer vaccines, engineered T-Cell therapies (TCR's), CARs?